A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects
Launched by ALNYLAM PHARMACEUTICALS · Dec 15, 2022
Trial Information
Current as of February 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called ALN-TTRSC04, which is being tested for its safety and how well it works in healthy volunteers. The main goal is to find out how the body handles this treatment and to see if it's safe to use. The trial is currently looking for participants aged between 18 and 75 years, and anyone interested must have a body mass index (BMI) within a specific range (between 18.0 and 30.0).
Participants in this trial will receive single doses of the treatment and will be monitored closely to check for any side effects or reactions. It's important to note that individuals with certain health conditions, like kidney issues or elevated liver enzymes, will not be eligible to participate. If you or someone you know fits the eligibility criteria and is looking for new treatment options, this could be an opportunity to contribute to research in this area.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Body mass index (BMI) ≥18.0 kg/m\^2 and ≤30 kg/m\^2 assessed at Screening.
- Exclusion Criteria:
- • Has an estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73m\^2 at screening.
- • Has alanine aminotransferase (ALT), aspartate aminotransferase (AST) or direct bilirubin above the upper limit of normal (ULN).
Trial Officials
Medical Director
Study Director
Alnylam Pharmaceuticals Inc
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneering biopharmaceutical company focused on the development of innovative therapies based on RNA interference (RNAi) technology. Founded in 2002, Alnylam is dedicated to transforming the treatment landscape for patients with genetically defined diseases by leveraging its proprietary platform to discover and develop novel therapeutics. With a robust pipeline of clinical programs targeting a range of conditions, including rare genetic disorders and prevalent diseases, Alnylam is committed to advancing scientific research and improving patient outcomes through cutting-edge medicine and rigorous clinical trials. The company emphasizes collaboration and transparency in its operations, fostering partnerships within the scientific community to drive innovation and enhance healthcare solutions globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials